APO Research
Talk to an analyst

APO RESEARCH · REPORT

Atypical Hemolytic Uremic Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Atypical Hemolytic Uremic Syndrome Drug Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchAtypical Hemolytic Uremic Syndrome Drug Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Atypical Hemolytic Uremic Syndrome Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Atypical Hemolytic Uremic Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Atypical Hemolytic Uremic Syndrome Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Atypical Hemolytic Uremic Syndrome Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Atypical Hemolytic Uremic Syndrome Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Atypical Hemolytic Uremic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Atypical Hemolytic Uremic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Atypical Hemolytic Uremic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Atypical Hemolytic Uremic Syndrome Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Atypical Hemolytic Uremic Syndrome Drug market include Amgen Inc, Omeros Corp, Kedrion SpA, greenovation Biotech GmbH, ChemoCentryx Inc, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc and Achillion Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Atypical Hemolytic Uremic Syndrome Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Atypical Hemolytic Uremic Syndrome Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Atypical Hemolytic Uremic Syndrome Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Atypical Hemolytic Uremic Syndrome Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Atypical Hemolytic Uremic Syndrome Drug Segment by Company

Amgen Inc

Omeros Corp

Kedrion SpA

greenovation Biotech GmbH

ChemoCentryx Inc

Alexion Pharmaceuticals Inc

Akari Therapeutics Plc

Achillion Pharmaceuticals Inc

Atypical Hemolytic Uremic Syndrome Drug Segment by Type

OMS-72

Mubodina

ETR-001

ET-006

CCX-168

ALN-CC5

Others

Atypical Hemolytic Uremic Syndrome Drug Segment by Application

Clinic

Hospital

Others

Atypical Hemolytic Uremic Syndrome Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Atypical Hemolytic Uremic Syndrome Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Atypical Hemolytic Uremic Syndrome Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Atypical Hemolytic Uremic Syndrome Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Atypical Hemolytic Uremic Syndrome Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atypical Hemolytic Uremic Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Atypical Hemolytic Uremic Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atypical Hemolytic Uremic Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Atypical Hemolytic Uremic Syndrome Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Atypical Hemolytic Uremic Syndrome Drug industry.

Chapter 3: Detailed analysis of Atypical Hemolytic Uremic Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Atypical Hemolytic Uremic Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Atypical Hemolytic Uremic Syndrome Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Atypical Hemolytic Uremic Syndrome Drug Industry Trends Table 2. Atypical Hemolytic Uremic Syndrome Drug Industry Drivers Table 3. Atypical Hemolytic Uremic Syndrome Drug Industry Opportunities and Challenges Table 4. Atypical Hemolytic Uremic Syndrome Drug Industry Restraints Table 5. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Company (2021-2026) Table 7. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share by Company (2021-2026) Table 9. Global Atypical Hemolytic Uremic Syndrome Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Atypical Hemolytic Uremic Syndrome Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Atypical Hemolytic Uremic Syndrome Drug Key Company Manufacturing Base & Headquarters Table 12. Global Atypical Hemolytic Uremic Syndrome Drug Company, Product Type & Application Table 13. Global Atypical Hemolytic Uremic Syndrome Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Atypical Hemolytic Uremic Syndrome Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of OMS-72 Table 18. Significant Companies of Mubodina Table 19. Significant Companies of ETR-001 Table 20. Significant Companies of ET-006 Table 21. Significant Companies of CCX-168 Table 22. Significant Companies of ALN-CC5 Table 23. Significant Companies of Others Table 24. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Type (2021-2026) & (k units) Table 26. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Type (2027-2032) & (k units) Table 27. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share by Type (2021-2026) Table 28. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share by Type (2027-2032) Table 29. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type (2021-2026) Table 33. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Clinic Table 35. Significant Companies of Hospital Table 36. Significant Companies of Others Table 37. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Application (2021-2026) & (k units) Table 39. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Application (2027-2032) & (k units) Table 40. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share by Application (2021-2026) Table 41. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share by Application (2027-2032) Table 42. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application (2021-2026) Table 46. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application (2027-2032) Table 47. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2021-2026) & (k units) Table 49. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2021-2026) Table 50. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2027-2032) & (k units) Table 51. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2027-2032) Table 52. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Region (2021-2026) Table 55. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Region (2027-2032) Table 57. Global Atypical Hemolytic Uremic Syndrome Drug Market Average Price (US$/unit) by Region (2021-2026) Table 58. Global Atypical Hemolytic Uremic Syndrome Drug Market Average Price (US$/unit) by Region (2027-2032) Table 59. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 60. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 62. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2021-2026) Table 63. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 64. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Country (2027-2032) Table 65. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Market Share by Country (2021-2026) Table 67. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Market Share by Country (2027-2032) Table 69. Amgen Inc Company Information Table 70. Amgen Inc Business Overview Table 71. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 73. Amgen Inc Recent Development Table 74. Omeros Corp Company Information Table 75. Omeros Corp Business Overview Table 76. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 78. Omeros Corp Recent Development Table 79. Kedrion SpA Company Information Table 80. Kedrion SpA Business Overview Table 81. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 83. Kedrion SpA Recent Development Table 84. greenovation Biotech GmbH Company Information Table 85. greenovation Biotech GmbH Business Overview Table 86. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 88. greenovation Biotech GmbH Recent Development Table 89. ChemoCentryx Inc Company Information Table 90. ChemoCentryx Inc Business Overview Table 91. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 93. ChemoCentryx Inc Recent Development Table 94. Alexion Pharmaceuticals Inc Company Information Table 95. Alexion Pharmaceuticals Inc Business Overview Table 96. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 98. Alexion Pharmaceuticals Inc Recent Development Table 99. Akari Therapeutics Plc Company Information Table 100. Akari Therapeutics Plc Business Overview Table 101. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 103. Akari Therapeutics Plc Recent Development Table 104. Achillion Pharmaceuticals Inc Company Information Table 105. Achillion Pharmaceuticals Inc Business Overview Table 106. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 108. Achillion Pharmaceuticals Inc Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Atypical Hemolytic Uremic Syndrome Drug Distributors List Table 112. Atypical Hemolytic Uremic Syndrome Drug Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Atypical Hemolytic Uremic Syndrome Drug Product Image Figure 2. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Atypical Hemolytic Uremic Syndrome Drug Sales (2021-2032) & (k units) Figure 5. Global Atypical Hemolytic Uremic Syndrome Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Atypical Hemolytic Uremic Syndrome Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. OMS-72 Image Figure 10. Mubodina Image Figure 11. ETR-001 Image Figure 12. ET-006 Image Figure 13. CCX-168 Image Figure 14. ALN-CC5 Image Figure 15. Others Image Figure 16. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share by Type (2021-2032) Figure 19. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type (2021-2032) Figure 22. Clinic Image Figure 23. Hospital Image Figure 24. Others Image Figure 25. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share by Application (2021-2032) Figure 28. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application (2021-2032) Figure 31. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 32. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 36. North America Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 42. South America Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Atypical Hemolytic Uremic Syndrome Drug Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Atypical Hemolytic Uremic Syndrome Drug Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • OMS-72
  • Mubodina
  • ETR-001
  • ET-006
  • CCX-168
  • ALN-CC5
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Amgen Inc
  • Omeros Corp
  • Kedrion SpA
  • greenovation Biotech GmbH
  • ChemoCentryx Inc
  • Alexion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • Achillion Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032)
  4. 1.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Atypical Hemolytic Uremic Syndrome Drug Market Dynamics
  1. 2.1 Atypical Hemolytic Uremic Syndrome Drug Industry Trends
  2. 2.2 Atypical Hemolytic Uremic Syndrome Drug Industry Drivers
  3. 2.3 Atypical Hemolytic Uremic Syndrome Drug Industry Opportunities and Challenges
  4. 2.4 Atypical Hemolytic Uremic Syndrome Drug Industry Restraints
3 Atypical Hemolytic Uremic Syndrome Drug Market by Company
  1. 3.1 Global Atypical Hemolytic Uremic Syndrome Drug Company Revenue Ranking in 2025
  2. 3.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Company (2021-2026)
  3. 3.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Atypical Hemolytic Uremic Syndrome Drug Average Price by Company (2021-2026)
  5. 3.5 Global Atypical Hemolytic Uremic Syndrome Drug Company Ranking (2024-2026)
  6. 3.6 Global Atypical Hemolytic Uremic Syndrome Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Atypical Hemolytic Uremic Syndrome Drug Company Product Type and Application
  8. 3.8 Global Atypical Hemolytic Uremic Syndrome Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Atypical Hemolytic Uremic Syndrome Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Atypical Hemolytic Uremic Syndrome Drug Market by Type
  1. 4.1 Atypical Hemolytic Uremic Syndrome Drug Type Introduction
  2. 4.1.1 OMS-72
  3. 4.1.2 Mubodina
  4. 4.1.3 ETR-001
  5. 4.1.4 ET-006
  6. 4.1.5 CCX-168
  7. 4.1.6 ALN-CC5
  8. 4.1.7 Others
  9. 4.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Type
  10. 4.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Type
  14. 4.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Type (2021-2032)
  16. 4.3.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type (2021-2032)
5 Atypical Hemolytic Uremic Syndrome Drug Market by Application
  1. 5.1 Atypical Hemolytic Uremic Syndrome Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Application
  6. 5.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Application
  10. 5.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application (2021-2032)
6 Atypical Hemolytic Uremic Syndrome Drug Regional Sales and Value Analysis
  1. 6.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2027-2032)
  5. 6.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Atypical Hemolytic Uremic Syndrome Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032)
  12. 6.6.2 North America Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032)
  21. 6.9.2 South America Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Atypical Hemolytic Uremic Syndrome Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Country, 2025 VS 2032
7 Atypical Hemolytic Uremic Syndrome Drug Country-level Sales and Value Analysis
  1. 7.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032)
  6. 7.4 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Atypical Hemolytic Uremic Syndrome Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Atypical Hemolytic Uremic Syndrome Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen Inc
  2. 8.1.1 Amgen Inc Company Information
  3. 8.1.2 Amgen Inc Business Overview
  4. 8.1.3 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  6. 8.1.5 Amgen Inc Recent Developments
  7. 8.2 Omeros Corp
  8. 8.2.1 Omeros Corp Company Information
  9. 8.2.2 Omeros Corp Business Overview
  10. 8.2.3 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  12. 8.2.5 Omeros Corp Recent Developments
  13. 8.3 Kedrion SpA
  14. 8.3.1 Kedrion SpA Company Information
  15. 8.3.2 Kedrion SpA Business Overview
  16. 8.3.3 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  18. 8.3.5 Kedrion SpA Recent Developments
  19. 8.4 greenovation Biotech GmbH
  20. 8.4.1 greenovation Biotech GmbH Company Information
  21. 8.4.2 greenovation Biotech GmbH Business Overview
  22. 8.4.3 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  24. 8.4.5 greenovation Biotech GmbH Recent Developments
  25. 8.5 ChemoCentryx Inc
  26. 8.5.1 ChemoCentryx Inc Company Information
  27. 8.5.2 ChemoCentryx Inc Business Overview
  28. 8.5.3 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  30. 8.5.5 ChemoCentryx Inc Recent Developments
  31. 8.6 Alexion Pharmaceuticals Inc
  32. 8.6.1 Alexion Pharmaceuticals Inc Company Information
  33. 8.6.2 Alexion Pharmaceuticals Inc Business Overview
  34. 8.6.3 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  36. 8.6.5 Alexion Pharmaceuticals Inc Recent Developments
  37. 8.7 Akari Therapeutics Plc
  38. 8.7.1 Akari Therapeutics Plc Company Information
  39. 8.7.2 Akari Therapeutics Plc Business Overview
  40. 8.7.3 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  42. 8.7.5 Akari Therapeutics Plc Recent Developments
  43. 8.8 Achillion Pharmaceuticals Inc
  44. 8.8.1 Achillion Pharmaceuticals Inc Company Information
  45. 8.8.2 Achillion Pharmaceuticals Inc Business Overview
  46. 8.8.3 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  48. 8.8.5 Achillion Pharmaceuticals Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Atypical Hemolytic Uremic Syndrome Drug Value Chain Analysis
  2. 9.1.1 Atypical Hemolytic Uremic Syndrome Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Atypical Hemolytic Uremic Syndrome Drug Sales Mode & Process
  6. 9.2 Atypical Hemolytic Uremic Syndrome Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Atypical Hemolytic Uremic Syndrome Drug Distributors
  9. 9.2.3 Atypical Hemolytic Uremic Syndrome Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst